Friday, November 2, 2018
Puma Biotec downgraded to Underweight from Overweight at JPMorgan
JPMorgan analyst Cory Kasimov double downgraded Puma Biotechnology to Underweight from Overweight and cut his price target for the shares to $23 from $83 following last night’s Q3 results. The analyst cites “significantly tempered” Nerlynx expectations for the downgrade following the revenue miss in Q3.
https://thefly.com/landingPageNews.php?id=2816303
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.